TY - JOUR
T1 - Prevention and Management of Graft-versus-Host Disease
T2 - Practical Recommendations
AU - Vogelsang, Georgia B.
AU - Morris, Lawrence E.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1993/5
Y1 - 1993/5
N2 - Graft-versus-host disease (GVHD) is the leading cause of failure of allogeneic bone marrow transplantation. The disease typically involves the skin, liver and gastrointestinal tract, with death frequently resulting from infectious complications. Cyclosporin-based drug combinations are the mainstay of GVHD prophylaxis. The major toxicity of cyclosporin is renal dysfunction, and optimal strategies of therapeutic drug monitoring to minimise toxicity and maximise clinical efficacy have yet to be devised. Initial treatment of established GVHD usually includes high dose corticosteroids. Patients failing to respond to first line therapy have a poor prognosis. Investigational approaches to decreasing the mortality associated with GVHD include using monoclonal antibodies directed at specific T cell subsets, and T cell depletion of bone marrow grafts.
AB - Graft-versus-host disease (GVHD) is the leading cause of failure of allogeneic bone marrow transplantation. The disease typically involves the skin, liver and gastrointestinal tract, with death frequently resulting from infectious complications. Cyclosporin-based drug combinations are the mainstay of GVHD prophylaxis. The major toxicity of cyclosporin is renal dysfunction, and optimal strategies of therapeutic drug monitoring to minimise toxicity and maximise clinical efficacy have yet to be devised. Initial treatment of established GVHD usually includes high dose corticosteroids. Patients failing to respond to first line therapy have a poor prognosis. Investigational approaches to decreasing the mortality associated with GVHD include using monoclonal antibodies directed at specific T cell subsets, and T cell depletion of bone marrow grafts.
UR - http://www.scopus.com/inward/record.url?scp=0027155517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027155517&partnerID=8YFLogxK
U2 - 10.2165/00003495-199345050-00004
DO - 10.2165/00003495-199345050-00004
M3 - Article
C2 - 7686462
AN - SCOPUS:0027155517
SN - 0012-6667
VL - 45
SP - 668
EP - 676
JO - Drugs
JF - Drugs
IS - 5
ER -